Key Points
- CEO Bradley Campbell sold 22,500 shares on March 2 at an average price of $14.35 for $322,875, reducing his stake by 2.20% to 998,680 shares; the trade was disclosed in an SEC filing.
- The stock traded near $14.34 (52‑week range $5.51–$14.38) with a $4.5B market cap; Amicus reported revenue up 23.7% year‑over‑year but missed EPS by $0.03 and posted a negative net margin.
- Analysts are mixed with a consensus "Hold" rating and $15.39 average target, while several institutional investors (including Goldman Sachs and UBS) recently increased their positions.
Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) CEO Bradley Campbell sold 22,500 shares of the company's stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $14.35, for a total value of $322,875.00. Following the transaction, the chief executive officer owned 998,680 shares in the company, valued at $14,331,058. This trade represents a 2.20% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Amicus Therapeutics Trading Up 0.1%
Shares of NASDAQ FOLD traded up $0.01 during trading on Thursday, reaching $14.34. The stock had a trading volume of 708,879 shares, compared to its average volume of 7,462,386. Amicus Therapeutics, Inc. has a fifty-two week low of $5.51 and a fifty-two week high of $14.38. The company has a debt-to-equity ratio of 1.43, a quick ratio of 1.88 and a current ratio of 2.84. The business's 50-day moving average price is $14.30 and its 200-day moving average price is $10.83. The company has a market cap of $4.50 billion, a P/E ratio of -179.25 and a beta of 0.43.
Amicus Therapeutics (NASDAQ:FOLD - Get Free Report) last announced its earnings results on Friday, February 20th. The biopharmaceutical company reported $0.10 EPS for the quarter, missing analysts' consensus estimates of $0.13 by ($0.03). The firm had revenue of $185.21 million for the quarter, compared to analysts' expectations of $185.00 million. Amicus Therapeutics had a negative net margin of 4.27% and a positive return on equity of 4.15%. The business's revenue was up 23.7% compared to the same quarter last year. During the same quarter last year, the business earned $0.09 earnings per share. On average, equities research analysts predict that Amicus Therapeutics, Inc. will post 0.15 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several equities analysts have commented on the stock. Citigroup restated a "neutral" rating and issued a $14.50 price target (down from $17.00) on shares of Amicus Therapeutics in a research note on Monday, December 22nd. The Goldman Sachs Group boosted their target price on Amicus Therapeutics from $9.00 to $11.00 and gave the stock a "neutral" rating in a research note on Wednesday, November 5th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Amicus Therapeutics in a research report on Monday, December 29th. Needham & Company LLC downgraded Amicus Therapeutics from a "buy" rating to a "hold" rating in a research report on Friday, December 19th. Finally, Leerink Partners lowered shares of Amicus Therapeutics from an "outperform" rating to a "market perform" rating and cut their target price for the stock from $17.00 to $14.50 in a research note on Monday, December 29th. Three investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Amicus Therapeutics currently has a consensus rating of "Hold" and an average target price of $15.39.
Get Our Latest Report on FOLD
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in FOLD. Goldman Sachs Group Inc. lifted its stake in Amicus Therapeutics by 7.7% during the first quarter. Goldman Sachs Group Inc. now owns 2,703,577 shares of the biopharmaceutical company's stock worth $22,061,000 after purchasing an additional 194,213 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Amicus Therapeutics by 11.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,072,474 shares of the biopharmaceutical company's stock worth $8,751,000 after purchasing an additional 113,803 shares in the last quarter. Intech Investment Management LLC raised its holdings in Amicus Therapeutics by 37.1% during the first quarter. Intech Investment Management LLC now owns 170,922 shares of the biopharmaceutical company's stock worth $1,395,000 after purchasing an additional 46,218 shares in the last quarter. Strs Ohio purchased a new stake in shares of Amicus Therapeutics during the 1st quarter worth approximately $30,000. Finally, CWM LLC boosted its holdings in shares of Amicus Therapeutics by 395.9% in the 2nd quarter. CWM LLC now owns 9,397 shares of the biopharmaceutical company's stock valued at $54,000 after buying an additional 7,502 shares in the last quarter.
About Amicus Therapeutics
(
Get Free Report)
Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.
The company's lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
